Latham & Watkins advised Exscientia on the deal, while Goodwin Procter LLP advised Novo Holdings.
Exscientia, the world leading artificial intelligence (AI) drug company, raised $60 million in a Series C financing round.
The financing was led by new investor Novo Holdings, with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital Partners (through certain LPs) – participating in the round.
The new capital will be used to expand Exscientia’s existing portfolio and pipeline, in addition to accelerating its international expansion, including the build-out of its presence in the US.
Exscientia is currently working on a joint initiative to identify COVID-19 antiviral treatments with Diamond Light Source and Scripps Research, as well as a ground-breaking collaboration with SRI International to combine fully automated synthetic chemistry with AI.
The Latham team advising Exscientia was led by London corporate partner Robbie McLaren (Picture), with associates Jon Fox and Faris Shoubber.
The Goodwin team was led by Sophie McGrath, Adam Thatcher and Matthew Shelley.
Involved fees earner: Sophie McGrath – Goodwin Procter; Matthew Shelley – Goodwin Procter; Jon Fox – Latham & Watkins; Robbie McLaren – Latham & Watkins; Faris Shoubber – Latham & Watkins; Adam Thatcher – Taylor Wessing;